Experimental drug for Alzheimer’s disease shows promise

Experimental drug for Alzheimer’s disease shows promise

Drug maker Eli Lilly on Monday announced promising results from a small study of an experimental Alzheimer’s disease drug called donanemab.

Comments are closed.

One small alcoholic drink a day is linked to an increased risk of atrial fibrillation
13 January 2021
Weaker skin barrier leads to faster uptake of chemicals
13 January 2021